Most Read Articles
Roshini Claire Anthony, 2 days ago

Patients undergoing chemotherapy for breast or haematological cancers could potentially reduce their risk of chemotherapy-related cardiotoxicity with the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists (ARBs), or beta-blockers as primary prevention, according to a systematic review and meta-analysis presented at the recent EuroEcho 2019 conference.

Tristan Manalac, 3 days ago
Users of electronic nicotine delivery systems are likely to have received a diagnosis of clinical depression in the past, according to a recent study.
Pearl Toh, 06 Dec 2019
Getting just under one extra hour of sleep per night can go a long way for the health of college students, who are often sleep-deprived, a study suggests.
Jairia Dela Cruz, Yesterday
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).

Superficial chemical peels relatively safe for darker skins

30 Aug 2018

Superficial chemical peel treatments are safe for darker skins, yielding relatively low complication rates, a recent study has shown. However, those with skin type VI are at higher risk of adverse events.

Researchers performed a retrospective analysis of 473 chemical peel treatments performed on 132 patients (mean age 40.3±10.9 years), whose skin types ranged from type III to type VI. Each patient received a mean of 3.5 peels, though most of the treatments were performed on females (388 vs 85).

Eighteen treatments (3.8 percent) resulted in either short-term (1.1 percent) or long-term (2.7 percent) side effects. The median duration of the side effects was 4.5 weeks and the most common complications were prolonged crust (2.3 percent) and erythema (1.9 percent).

Side effects were most commonly observed in those with skin type IV (5.4 percent), type III (2.7 percent) and type VI (12.5 percent).

Relative to skin type III, those with type VI were at significantly higher risks of side effects (odds ratio [OR], 5.14; 95 percent CI, 1.21–21.8; p=0.0118), while those with skin type V demonstrated a nonsignificantly lower risk (OR, 0.67; 0.15–3.05; p=0.0659).

Side effects were most frequent in single peels (4.7 percent), treatments that used glycolic acid (6.03 percent) and in patients who had previously received chemical peels. On the other hand, peels performed in the winter had a nonsignificantly lower likelihood of resulting in side effects than those performed in the spring (OR, 0.13 0.02–1.02; p=0.078).

Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 2 days ago

Patients undergoing chemotherapy for breast or haematological cancers could potentially reduce their risk of chemotherapy-related cardiotoxicity with the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists (ARBs), or beta-blockers as primary prevention, according to a systematic review and meta-analysis presented at the recent EuroEcho 2019 conference.

Tristan Manalac, 3 days ago
Users of electronic nicotine delivery systems are likely to have received a diagnosis of clinical depression in the past, according to a recent study.
Pearl Toh, 06 Dec 2019
Getting just under one extra hour of sleep per night can go a long way for the health of college students, who are often sleep-deprived, a study suggests.
Jairia Dela Cruz, Yesterday
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).